SYRE Stock Analysis: Spyre Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.523m USD | 12M Return: 515.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 143M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Spyre Therapeutics (NASDAQ: SYRE) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that develops antibody-based therapeutics for inflammatory bowel disease (IBD) and rheumatic diseases. The company was incorporated in 2013 and was formerly known as Aeglea BioTherapeutics before rebranding in November 2023.
Spyres pipeline targets well-validated mechanisms in IBD, including α4β7 integrin (SPY001, in Phase 2 for ulcerative colitis and Crohns disease), TL1A (SPY002 and SPY072), and IL-23 (SPY003, in Phase 2). The company is also advancing combination therapies that pair these mechanisms (SPY120, SPY130, and SPY230) to address overlapping inflammatory pathways. As a clinical-stage biotech without approved products, Spyres business model relies on continued R&D investment, clinical trial execution, and access to capital markets to advance its candidates toward potential regulatory approval and commercialization.
- SPY001 phase 2 ulcerative colitis data readout
- Anti-TL1A pipeline competition with Merck and Prometheus
- Cash burn and runway extend clinical operations
| Net Income: -179.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 5.49 > 1.0 |
| NWC/Revenue: 750.1% < 20% (prev 56.3k%; Δ -55.6k% < -1%) |
| CFO/TA -0.24 > 3% & CFO -185.8m > Net Income -179.4m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 8.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (346.0m) vs 12m ago 474.2% < -2% |
| Gross Margin: -89.68% > 18% (prev -8.80%; Δ -80.88% > 0.5%) |
| Asset Turnover: 13.57% > 50% (prev 0.16%; Δ 13.41% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 764.0m - Total Current Liabilities 85.2m) / Total Assets 764.0m |
| B: -1.57 (Retained Earnings -1.20b / Total Assets 764.0m) |
| C: -0.35 (EBIT TTM -231.6m / Avg Total Assets 666.9m) |
| D: 7.20 (Book Value of Equity 670.8m / Total Liabilities 93.1m) |
| Altman-Z'' = 5.95 = AAA |
As of July 08, 2026, the stock is trading at USD 94.23 with a total of 1,305,750 shares traded. Over the past week, the price has changed by +4.51%, over one month by +30.88%, over three months by +84.04% and over the past year by +515.88%.
Current recommended Stop Loss: 86.90 (which is 7.8% or 1.4 ATR below the current price).
Spyre Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy SYRE.
- StrongBuy: 10
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 100.5 | 6.6% |
P/S = 537.537
P/B = 14.609
Revenue TTM = 90.5m USD
EBIT TTM = -231.6m USD
EBITDA TTM = -221.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 6.78b USD (7.52b + (null Debt) - CCE 741.5m)
Interest Coverage Ratio = unknown (Ebit TTM -231.6m / Interest Expense TTM 0.0)
EV/FCF = -36.50x (Enterprise Value 6.78b / FCF TTM -185.8m)
FCF Yield = -2.74% (FCF TTM -185.8m / Enterprise Value 6.78b)
FCF Margin = -205.3% (FCF TTM -185.8m / Revenue TTM 90.5m)
Net Margin = -198.3% (Net Income TTM -179.4m / Revenue TTM 90.5m)
Gross Margin = -89.68% ((Revenue TTM 90.5m - Cost of Revenue TTM 171.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev 50.0%)
Tobins Q-Ratio = 8.88 (Enterprise Value 6.78b / Total Assets 764.0m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -183.0m (EBIT -231.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.97 (Total Current Assets 764.0m / Total Current Liabilities 85.2m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -221.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -185.8m)
Total Stockholder Equity = 574.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.91% (Net Income -179.4m / Total Assets 764.0m)
RoE = -31.25% (Net Income TTM -179.4m / Total Stockholder Equity 574.2m)
RoCE = -34.12% (EBIT -231.6m / Capital Employed (Total Assets 764.0m - Current Liab 85.2m))
RoIC = -27.14% (negative operating profit) (NOPAT -183.0m / Invested Capital 674.3m)
WACC = 12.30% (E(7.52b)/V(7.52b) * Re(12.30%) + (debt-free company))
Discount Rate = 12.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 242.4%
[DCF] Fair Price = unknown (Cash Flow -185.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.75 | Chg30d=-4.42% | Revisions=-40% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.73 | Chg30d=-4.66% | Revisions=-40% | Analysts=13
EPS current Year (2026-12-31): EPS=-2.95 | Chg30d=-3.88% | Revisions=-40% | GrowthEPS=-48.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.13 | Chg30d=-3.16% | Revisions=-40% | GrowthEPS=-6.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -73% (up=0, down=8)